Biomarkers Predicting the Effect of Anti-TNF Treatment in Pediatric and Adult Inflammatory Bowel Disease

Trial Profile

Biomarkers Predicting the Effect of Anti-TNF Treatment in Pediatric and Adult Inflammatory Bowel Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2013

At a glance

  • Drugs Adalimumab (Primary) ; Infliximab (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 20 Nov 2013 Profile updated
    • 04 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top